BDRX
Biodexa Pharmaceuticals Plc
NASDAQ · Healthcare · Biotechnology · GB
$0.73
−8.74%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.78
From 52W high−98.66%
Volume545767.00
Market cap$751218.18
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.78
From 52W high
−98.66%
Volume
545767.00
Market cap
$751218.18
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
39.4
MomentumView details →
1D Return
−8.74%
YTD Return
−93.37%
SummaryUpdated Jun 1, 2026
Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) is a Belgian-based drug delivery technology company founded in 2000 and headquartered in Cardiff, United Kingdom. Originally known as Midatech Pharma plc, the company rebranded to Biodexa Pharmaceuticals in March 2023. The company went public in December 2015 and focuses on developing innovative bio-delivery and biodistribution technologies for medicines, operating internationally with a particular emphasis on treating challenging medical conditions including brain tumors and psychiatric disorders.
Similar companies
Latest newsMore news →
Biodexa Pharmaceuticals PLC entered into a warrant exercise agreement with an existing accredited investor for the exercise of 2,204,218 outstanding warrants at $1.05 per ADS, raising approximately $2.3 million in gross proceeds.5d agoBiodexa Pharmaceuticals PLC announced its unaudited interim results for the six months ended June 30, 2026.9d agoBiodexa Pharmaceuticals announced that its Serenta registrational Phase 3 trial for eRapa in Familial Adenomatous Polyposis has recruited 87 of 168 planned subjects, exceeding the halfway point.32d ago